English  |  正體中文  |  简体中文  |  Items with full text/Total items : 1592/1691
Visitors : 1197234      Online Users : 253
RC Version 5.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Adv. Search
LoginUploadHelpAboutAdminister

Please use this identifier to cite or link to this item: http://140.112.115.32:8080/ir/handle/987654321/1198

Title: Alzheimer's Disease: Aging, Insomnia and Epigenetics
Authors: Tzong-Yuan Wu;Chih-Ping Chen;Tzyy-Rong Jinn
Contributors: 生醫所
Date: 2010-12-01
Issue Date: 2015-03-16 15:40:39 (UTC+8)
Abstract: Alzheimer's disease (AD) is the most common form of dementia. Severe memory loss, confusion, and impaired cognitive abilities characterize AD. It was only a century after Alzheimer's discovery that scientists were able to shed light on the mystery of its cause, but AD has also become a globally important health issue and the treatment of AD is a challenge for modern medicine. At present, there are five drugs approved in the United States for the treatment of AD, namely, donepezil, galantamine, rivastigmine, and tacrine (which are all cholinesterase inhibitors); and memantine (which is a glutamate receptor antagonist). However, these drugs show only modest effects on AD patients. Thus, new investigations are necessary for pharmacological development in AD. This brief review focuses on new studies that demonstrate the link between epigenetics and AD, and explores the possibility that insomnia may be one factor that effects AD.
Relation: Taiwanese Journal of Obstetrics and Gynecology, 49(4), 468-472. doi:10.1016/S1028-4559(10)60099-X
https://doi.org/10.1016/S1028-4559(10)60099-X
Appears in Collections:[生物醫學研究所] 期刊論文

Files in This Item:

File SizeFormat
index.html0KbHTML154View/Open


All items in MMCIR are protected by copyright, with all rights reserved.

 


DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback